A case of COVID-19 pneumonia with cerebral hemorrhage

We agree with Dr. Klok that thromboprophylactic dose low molecular weight heparin should be recommended for all the critically ill patients with 2019 novel coronavirus disease (COVID-19) pneumonia [1]. The very high cumulative incidence of thrombotic complications raises the question if therapeutic anticoagulation should be considered for severe COVID-19 pneumonia patients. As previously reported, patients with COVID-19 may show a wide range of neurologic manifestations, such as loss of consciousness, headache, seizures, ageusia, hyposmia and dysphagia.
Source: Thrombosis Research - Category: Hematology Authors: Tags: Letter to the Editors-in-Chief Source Type: research